

# Joerg Albrecht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5266855/publications.pdf>

Version: 2024-02-01

41  
papers

1,253  
citations

858243

12  
h-index

563245

28  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1812  
citing authors

#	ARTICLE	IF	CITATIONS
1	Another anti-interleukin ( IL ) inhibitor: is there an advantage of blocking ILA and ILF?. British Journal of Dermatology, 2022, 186, 603-604.	1.4	0
2	Guidebook to Dermatological Diagnosis. Susan Burgin. New York, NY: McGraw Hill, 2021; 624 pp. ISBN: 978-0-07-173875-0. Price £56.34.. British Journal of Dermatology, 2022, 186, 914-915.	1.4	0
3	The Power of Topical Steroids. JAMA Dermatology, 2022, 158, 727.	2.0	1
4	Dapsone-induced agranulocytosis: symptoms may alert more reliably than the current blood monitoring protocol. British Journal of Dermatology, 2021, 184, 962-963.	1.4	3
5	At 180 days hidradenitis suppurativa readmission rate is comparable to heart failure: Analysis of the nationwide readmissions database. Journal of the American Academy of Dermatology, 2021, , .	0.6	1
6	Long-term efficacy: the new gold standard?. British Journal of Dermatology, 2021, 185, 1086.	1.4	0
7	Viability considerations in implementing same-class topical steroid substitution. Journal of the American Academy of Dermatology, 2020, 83, e441.	0.6	0
8	Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology. Journal of the American Academy of Dermatology, 2020, 83, 691-699.	0.6	2
9	Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management". Journal of the American Academy of Dermatology, 2019, , .	0.6	2
10	Who likes to perform the Psoriasis Area and Severity Index?. British Journal of Dermatology, 2019, 180, 260-261.	1.4	0
11	Understanding cutaneous lupus erythematosus: a step forward. British Journal of Dermatology, 2019, 180, 1292-1293.	1.4	1
12	Methodology of Evaluating the Laboratory Monitoring of Terbinafine Therapy. JAMA Dermatology, 2019, 155, 756.	2.0	1
13	The recommendations about laboratory monitoring on isotretinoin are reasonable, but the patient numbers cannot prove it. Journal of the American Academy of Dermatology, 2019, 85, e367.	0.6	0
14	Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa?. British Journal of Dermatology, 2019, 180, 949-950.	1.4	15
15	Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. British Journal of Dermatology, 2019, 180, 1262-1263.	1.4	0
16	Professor Sidney Barski (1918-2018). British Journal of Dermatology, 2019, 180, 234-235.	1.4	0
17	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. Journal of the American Academy of Dermatology, 2019, 80, 577-578.	0.6	7
18	Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic. British Journal of Dermatology, 2019, 180, 749-755.	1.4	35

#	ARTICLE	IF	CITATIONS
19	Optimizing case reports and case series: guidance on how to improve quality. <i>British Journal of Dermatology</i> , 2018, 178, 1257-1262.	1.4	6
20	When to switch biologics: some answers, but lots of questions too. <i>British Journal of Dermatology</i> , 2018, 178, 20-20.	1.4	0
21	Terbinafine-induced liver injury may be asymptomatic: need for regular monitoring: reply from the authors. <i>British Journal of Dermatology</i> , 2018, 178, 808-809.	1.4	0
22	Development of resistance to <i>Mycobacterium tuberculosis</i> is manageable in hidradenitis suppurativa. Response to "Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?" <i>British Journal of Dermatology</i> , 2018, 178, 300-300.	1.4	4
23	Put the ducks in a row - which biologic to use first?. <i>British Journal of Dermatology</i> , 2018, 179, 241-242.	1.4	0
24	Paternal drug exposure: plenty of confounders, few conclusions. <i>British Journal of Dermatology</i> , 2017, 176, 847-848.	1.4	1
25	Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. <i>British Journal of Dermatology</i> , 2017, 177, 960-966.	1.4	28
26	Switching expensive drugs with frequently diminishing value. <i>British Journal of Dermatology</i> , 2017, 177, 338-339.	1.4	1
27	Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 784-786.	0.6	9
28	Positive about negative: no need for a pink cloud of fluff and justifications. <i>British Journal of Dermatology</i> , 2017, 177, 1-3.	1.4	1
29	Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2017, 177, 1279-1284.	1.4	34
30	A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price. <i>British Journal of Dermatology</i> , 2016, 174, 1183-1184.	1.4	0
31	The state and consequences of dermatology drug prices in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 603-605.	0.6	15
32	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , 2016, 36, 319-323.	1.1	351
33	Clinical trials in theBJD: more meat, less salami. <i>British Journal of Dermatology</i> , 2015, 173, 1353-1354.	1.4	6
34	The Reach of the 340B Drug Pricing Program. <i>JAMA Dermatology</i> , 2015, 151, 923.	2.0	5
35	A survey of case reports and case series of therapeutic interventions in theArchives of Dermatology. <i>International Journal of Dermatology</i> , 2009, 48, 592-597.	0.5	21
36	The role of case reports in evidence-based practice, with suggestions for improving their reporting. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 412-418.	0.6	59

#	ARTICLE	IF	CITATIONS
37	Skin involvement and outcome measures in systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S52-9.	0.4	17
38	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2005, 125, 889-894.	0.3	376
39	Case reports and case series from had significant impact on medical literature. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 1227-1232.	2.4	135
40	Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 839-849.	0.8	103
41	The meaning of "safe and effective". <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 144-147.	0.6	11